Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a GnRH agonist presented as an injectable formulation for subcutaneous use. It is employed in hormone therapy to reduce sex hormone production in conditions such as prostate cancer, endometriosis, precocious puberty and uterine fibroids.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Leptoprol is manufactured under EU GMP guidelines to ensure consistent potency and safety.

Leuprorelin is used in hormone‑dependent conditions where suppression of the gonadal axis is required. - Prostate cancer: reduces testosterone levels to slow tumor growth. - Endometriosis: lowers estrogen production to alleviate pelvic pain and lesion progression. - Precocious puberty: suppresses early activation of the hypothalamic‑pituitary‑gonadal axis. - Uterine fibroids: decreases estrogen stimulation to reduce fibroid size and bleeding.

Leuprorelin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Injection site pain or erythema - Headache - Fatigue

Serious or Rare Side Effects: - Cardiovascular events such as myocardial infarction - Severe allergic reactions including anaphylaxis - Bone mineral density loss leading to osteoporosis

When prescribing Leuprorelin, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate history of heart disease before initiating therapy. - Bone health monitoring: perform baseline bone density tests and consider calcium/vitamin D supplementation. - Metabolic evaluation: monitor glucose and lipid profiles as hormone changes may affect metabolism. - Visual disturbances: advise patients to report any sudden vision changes promptly. - Hormone‑dependent tumor surveillance: continue regular imaging for prostate cancer or fibroid progression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antidiabetic agents: GnRH agonist‑induced hormonal changes may affect blood glucose control. - CYP450 inducers: may reduce effectiveness of concomitant hormonal therapies metabolized by this pathway.

Moderate Interactions (Monitor Closely): - Hormone replacement therapy: concurrent use may blunt intended hormone suppression. - Anticoagulants: monitor for bleeding risk if injection site bruising occurs. - Thyroid hormone replacement: adjust dosing as GnRH agonist can influence thyroid function tests.